MI:RNA, the Edinburgh veterinary diagnostics company, said it has concluded a second venture capital (VC) led financing — which has raised $3.6 million and accelerates a rapid period of expansion and commercial progress for the company.

MI:RNA uses biomarkers and advanced modelling to diagnose veterinary disease earlier.

Having completed a $4 million Series A funding rounding in July 2024, the second round attracted participation from existing investors — and two new investment funds.

Funds have been raised from existing investors including NovaQuest, Kyoritsu Holdings Corporation, VANE (Angel Syndicate), Animal Health Angels, Equity Gap, Gabriel, Scottish Enterprise, as well as new investors Holstein UK and AniVC.

Eve Hanks, CEO and founder of MI:RNA, said: “Our technology uses biomarkers and advanced modelling to spot health problems in animals earlier than ever before with a simple blood sample. With this incredible new approach, we can diagnose, monitor, and predict how diseases will develop for happier, healthier pets and a sustainable future for agriculture.

“The opportunity to deploy our diagnostic platform globally through our partner laboratories is taking shape, and this positive support from our investors not only validates the strength of our technology and market approach, it also accelerates our continued development and technological advancement as we work to bring critical diagnostic solutions into the hands of those who need them most.

“This is a positive milestone for us that will allow us to scale more quickly, as we work to give animals longer, healthier lives.”

Brian Axe, Partner at NovaQuest Capital Management said: “The continued overwhelming support for MI:RNA is a testament to the promise of this company, the team, and this innovative platform. We are excited to see this technology deployed in the market.”